Login to Your Account

Second Phase III Ongoing

Cell Genesys Falls 70% as Patient Deaths Derail GVAX Phase III

By Trista Morrison

Thursday, August 28, 2008
In yet another setback for cancer vaccines, Cell Genesys Inc. terminated one of its two Phase III trials with prostate cancer vaccine GVAX. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription